医学
彭布罗利珠单抗
化学免疫疗法
背景(考古学)
疾病
无容量
免疫学
免疫疗法
自身免疫性疾病
临床试验
内科学
免疫系统
生物
古生物学
作者
Andrea Spagnoletti,Marco Platania,Marta Brambilla,Mario Occhipinti,Luca Canziani,Antonello D. Cabras,Leonardo Provenzano,Alberto Giovanni Leone,Paolo Ambrosini,Arsela Prelaj
标识
DOI:10.1177/03008916211067565
摘要
The use of immune checkpoint inhibitors (ICIs) offers new possibilities in modern treatment of many types of cancers. Few data regarding safety and efficacy of ICIs are available, and are mainly from retrospective studies and case reports rather than from clinical trials, in the context of preexisting autoimmune disease, mainly due to the risk of severe toxicity. We present an unexpected life-threatening reactivation of systemic lupus erythematosus after one dose of chemo-immunotherapy with pembrolizumab for oligometastatic non-small-cell lung cancer. We analyze data coming from the published literature in this setting and discuss the risk–benefit balance of immunotherapy in patients with preexisting severe autoimmune disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI